<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465436</url>
  </required_header>
  <id_info>
    <org_study_id>16900</org_study_id>
    <secondary_id>H8H-CD-LAHP</secondary_id>
    <secondary_id>COL-MIG-105</secondary_id>
    <secondary_id>2011-003229-88</secondary_id>
    <nct_id>NCT03465436</nct_id>
  </id_info>
  <brief_title>A Study of Lasmiditan on the Heart in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 4-way Crossover Study to Compare the Effects on the Cardiac De- and Repolarization Duration as Well as Other Cardiac Safety Parameters of Two Doses of Oral Lasmiditan (100 mg and 400 mg) With Those of Moxifloxacin (400 mg) and Placebo in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CoLucid Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine how two doses of lasmiditan affected the heart in
      healthy participants. The study also evaluated how much lasmiditan got into the blood stream
      and how long it took the body to get rid of it. Information about side effects was collected.
      The study lasted a maximum of 46 days for each participant, not including screening.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2011</start_date>
  <completion_date type="Actual">December 20, 2011</completion_date>
  <primary_completion_date type="Actual">December 20, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin</measure>
    <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
    <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Time Matched Baseline in Mean Individually-Corrected QT (QTcI) Values of Lasmiditan and Moxifloxacin</measure>
    <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
    <description>The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for participant pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Cardiac Intervals: RR Interval of Lasmiditan and Moxifloxacin</measure>
    <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
    <description>ECGs were used to calculate cardiac intervals. The RR interval is the time between two R waves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Cardiac Intervals:QRS of Lasmiditan and Moxifloxacin</measure>
    <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
    <description>ECGs were used to calculate cardiac intervals. The QRS interval is the time the segment of the ECG that corresponds to depolarization of the ventricles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Heart Rate (HR) of Lasmiditan and Moxifloxacin</measure>
    <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
    <description>Heart rate was determined during ambulatory blood pressure monitoring (ABPM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incidents in Electrocardiogram (ECG) Abnormalities in QTcF Interval Greater Than 450 Milliseconds</measure>
    <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
    <description>ECGs were assessed for morphology abnormalities or changes in QTcf interval greater than 450 milliseconds by a board-certified cardiologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan</measure>
    <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
    <description>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan</measure>
    <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
    <description>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>100 milligrams (mg) Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>100 mg administered orally (PO)</description>
    <arm_group_label>100 milligrams (mg) Lasmiditan</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>400 mg administered PO</description>
    <arm_group_label>400 mg Lasmiditan</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered for lasmiditan or moxifloxacin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400 mg moxifloxacin administered PO</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index within 18.5 and 29.9 kilograms per meter squared (kg/mÂ²)

          -  In good physical and mental health as determined by the following:

               -  Complete medical history

               -  Complete physical examination

               -  Vital signs including blood pressure (supine and standing), heart rate (supine
                  and standing), respiratory rate, and temperature

               -  Standard 12-lead ECG (triplicate ECG), followed by a 24-hour Holter ECG for
                  arrhythmia monitoring

               -  Clinical laboratory tests

        Exclusion Criteria:

          -  Any of the following cardiac abnormalities on safety screening ECG:

               -  QTcF interval &gt;430 milliseconds (ms) for males, &gt;450 ms for females

               -  Unusual T wave morphology or flattened low voltage T waves

               -  PR interval &gt;240 ms or &lt;110 ms

               -  Second-degree or third-degree atrioventricular block

               -  ECG evidence of complete left or right bundle branch block

               -  Intraventricular conduction delay or QRS duration &gt;110 ms

               -  Supine resting heart rate &lt;45 beats per minute (bpm) or &gt;90 bpm

               -  Pathological Q-waves

               -  Evidence of ventricular pre-excitation

          -  Participants with a history of syncope, cardiac arrest, cardiac arrhythmia or torsade
             de pointes, or structural heart disease

          -  Participants with a family history of Long QT syndrome

          -  History of allergic hypersensitivity to lasmiditan or any component of the
             formulations

          -  History or current evidence of abuse of any drug substance, licit or illicit,
             including alcohol; a positive urine screen for drugs of abuse

          -  Participants with a history of postural hypotension or fainting

          -  Participant is not able to understand and comply with study requirements, instructions
             and study restrictions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <results_first_submitted>November 8, 2019</results_first_submitted>
  <results_first_submitted_qc>January 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2020</results_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All randomized participants who received at least 1 dose of study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1 ABDC</title>
          <description>Day 1 of each treatment period with a washout period of 7-14 days.
A. 100 mg lasmiditan PO B. 400 mg lasmiditan PO D. 400 mg moxifloxacin PO (plus placebo) C. Placebo matched</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2 BCAD</title>
          <description>Day 1 of each treatment period with a washout period of 7-14 days.
B. 400 mg lasmiditan PO C. Placebo matched A. 100 mg lasmiditan PO D. 400 mg moxifloxacin PO (plus placebo)</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3 CDBA</title>
          <description>Day 1 of each treatment period with a washout period of 7-14 days.
C. Placebo matched D. 400 mg moxifloxacin PO (plus placebo) B. 400 mg lasmiditan PO A. 100 mg lasmiditan PO</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4 DACB</title>
          <description>Day 1 of each treatment period with a washout period of 7-14 days.
D. 400 mg moxifloxacin PO (plus placebo) A. 100 mg lasmiditan PO C. Placebo matched B. 400 mg lasmiditan PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1 ABDC</title>
          <description>Day 1 of each treatment period with a washout period of 7-14 days.
A. 100 mg lasmiditan PO B. 400 mg lasmiditan PO D. 400 mg moxifloxacin PO (plus placebo) C. Placebo matched</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2 BCAD</title>
          <description>Day 1 of each treatment period with a washout period of 7-14 days.
B. 400 mg lasmiditan PO C. Placebo matched A. 100 mg lasmiditan PO D. 400 mg moxifloxacin PO (plus placebo)</description>
        </group>
        <group group_id="B3">
          <title>Sequence 3 CDBA</title>
          <description>Day 1 of each treatment period with a washout period of 7-14 days.
C. Placebo matched D. 400 mg moxifloxacin PO (plus placebo) B. 400 mg lasmiditan PO A. 100 mg lasmiditan PO</description>
        </group>
        <group group_id="B4">
          <title>Sequence 4 DACB</title>
          <description>Day 1 of each treatment period with a washout period of 7-14 days.
D. 400 mg moxifloxacin PO (plus placebo) A. 100 mg lasmiditan PO C. Placebo matched B. 400 mg lasmiditan PO</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="12.3"/>
                    <measurement group_id="B2" value="38.4" spread="11.7"/>
                    <measurement group_id="B3" value="37.5" spread="10.8"/>
                    <measurement group_id="B4" value="40.7" spread="9.1"/>
                    <measurement group_id="B5" value="39.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin</title>
        <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.</description>
        <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and have evaluable QTcF data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered PO in 1 of 4 treatment periods</description>
          </group>
          <group group_id="O2">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered PO in 1 of 4 treatment periods</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin administered PO in 1 of 4 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin</title>
          <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.</description>
          <population>All randomized participants who received at least 1 dose of study drug and have evaluable QTcF data.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 minutes postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.90" spread="7.20"/>
                    <measurement group_id="O2" value="-9.27" spread="6.29"/>
                    <measurement group_id="O3" value="-5.49" spread="5.52"/>
                    <measurement group_id="O4" value="1.90" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.42" spread="5.83"/>
                    <measurement group_id="O2" value="-4.58" spread="8.13"/>
                    <measurement group_id="O3" value="-3.94" spread="5.15"/>
                    <measurement group_id="O4" value="8.36" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.63" spread="5.98"/>
                    <measurement group_id="O2" value="-3.07" spread="7.91"/>
                    <measurement group_id="O3" value="-3.68" spread="4.66"/>
                    <measurement group_id="O4" value="7.63" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.96" spread="7.08"/>
                    <measurement group_id="O2" value="-1.12" spread="8.10"/>
                    <measurement group_id="O3" value="-3.83" spread="5.28"/>
                    <measurement group_id="O4" value="8.16" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.26" spread="7.36"/>
                    <measurement group_id="O2" value="0.15" spread="8.67"/>
                    <measurement group_id="O3" value="-2.89" spread="4.99"/>
                    <measurement group_id="O4" value="8.12" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.81" spread="6.95"/>
                    <measurement group_id="O2" value="2.06" spread="8.18"/>
                    <measurement group_id="O3" value="-2.04" spread="5.71"/>
                    <measurement group_id="O4" value="10.01" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.39" spread="7.63"/>
                    <measurement group_id="O2" value="3.58" spread="6.88"/>
                    <measurement group_id="O3" value="-1.85" spread="4.59"/>
                    <measurement group_id="O4" value="10.37" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.12" spread="6.89"/>
                    <measurement group_id="O2" value="4.77" spread="7.49"/>
                    <measurement group_id="O3" value="-2.34" spread="5.65"/>
                    <measurement group_id="O4" value="9.39" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.33" spread="7.32"/>
                    <measurement group_id="O2" value="-0.18" spread="7.38"/>
                    <measurement group_id="O3" value="-3.39" spread="6.59"/>
                    <measurement group_id="O4" value="4.91" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.74" spread="7.16"/>
                    <measurement group_id="O2" value="-1.84" spread="7.82"/>
                    <measurement group_id="O3" value="-3.99" spread="7.11"/>
                    <measurement group_id="O4" value="3.90" spread="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.73" spread="5.72"/>
                    <measurement group_id="O2" value="-0.41" spread="6.99"/>
                    <measurement group_id="O3" value="-1.79" spread="5.91"/>
                    <measurement group_id="O4" value="4.63" spread="7.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="7.51"/>
                    <measurement group_id="O2" value="0.38" spread="7.06"/>
                    <measurement group_id="O3" value="0.45" spread="6.18"/>
                    <measurement group_id="O4" value="6.61" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-3.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.41</ci_lower_limit>
            <ci_upper_limit>-1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-3.54</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.18</ci_lower_limit>
            <ci_upper_limit>-1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-4.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.77</ci_lower_limit>
            <ci_upper_limit>-2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-3.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.14</ci_lower_limit>
            <ci_upper_limit>-1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-2.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.41</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.84</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.53</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>0.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-1.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.22</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-2.73</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.88</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-2.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.77</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>0.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.90</ci_lower_limit>
            <ci_upper_limit>2.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-3.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.56</ci_lower_limit>
            <ci_upper_limit>-2.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.75</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>0.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>2.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>2.58</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>4.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>2.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>4.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>3.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.85</ci_lower_limit>
            <ci_upper_limit>6.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>5.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.61</ci_lower_limit>
            <ci_upper_limit>6.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>6.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.99</ci_lower_limit>
            <ci_upper_limit>8.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>3.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>5.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>2.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>4.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>1.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>3.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.21</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>7.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.03</ci_lower_limit>
            <ci_upper_limit>9.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>12.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.47</ci_lower_limit>
            <ci_upper_limit>14.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>11.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.54</ci_lower_limit>
            <ci_upper_limit>13.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>11.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.97</ci_lower_limit>
            <ci_upper_limit>13.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>10.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.17</ci_lower_limit>
            <ci_upper_limit>12.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>11.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.10</ci_lower_limit>
            <ci_upper_limit>13.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>12.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.32</ci_lower_limit>
            <ci_upper_limit>14.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>11.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.83</ci_lower_limit>
            <ci_upper_limit>13.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>8.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.10</ci_lower_limit>
            <ci_upper_limit>10.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>7.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.66</ci_lower_limit>
            <ci_upper_limit>10.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>6.35</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.32</ci_lower_limit>
            <ci_upper_limit>8.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>6.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.88</ci_lower_limit>
            <ci_upper_limit>8.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Time Matched Baseline in Mean Individually-Corrected QT (QTcI) Values of Lasmiditan and Moxifloxacin</title>
        <description>The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for participant pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
        <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and have evaluable QTcI data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin administered PO in 1 of 4 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Time Matched Baseline in Mean Individually-Corrected QT (QTcI) Values of Lasmiditan and Moxifloxacin</title>
          <description>The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for participant pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
          <population>All randomized participants who received at least 1 dose of study drug and have evaluable QTcI data.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 minutes postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.92" spread="7.62"/>
                    <measurement group_id="O2" value="-10.56" spread="8.00"/>
                    <measurement group_id="O3" value="-5.27" spread="6.04"/>
                    <measurement group_id="O4" value="2.24" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.50" spread="7.74"/>
                    <measurement group_id="O2" value="-6.90" spread="8.98"/>
                    <measurement group_id="O3" value="-3.35" spread="5.52"/>
                    <measurement group_id="O4" value="8.96" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.39" spread="6.93"/>
                    <measurement group_id="O2" value="-4.73" spread="8.29"/>
                    <measurement group_id="O3" value="-2.81" spread="5.58"/>
                    <measurement group_id="O4" value="8.61" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.74" spread="8.34"/>
                    <measurement group_id="O2" value="-2.65" spread="8.56"/>
                    <measurement group_id="O3" value="-3.49" spread="5.82"/>
                    <measurement group_id="O4" value="8.29" spread="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.90" spread="9.42"/>
                    <measurement group_id="O2" value="-1.80" spread="8.84"/>
                    <measurement group_id="O3" value="-2.44" spread="5.61"/>
                    <measurement group_id="O4" value="8.40" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.08" spread="8.29"/>
                    <measurement group_id="O2" value="-0.13" spread="8.63"/>
                    <measurement group_id="O3" value="-1.70" spread="6.10"/>
                    <measurement group_id="O4" value="11.01" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.86" spread="8.72"/>
                    <measurement group_id="O2" value="1.90" spread="7.48"/>
                    <measurement group_id="O3" value="-1.67" spread="5.01"/>
                    <measurement group_id="O4" value="11.43" spread="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="8.07"/>
                    <measurement group_id="O2" value="3.27" spread="8.44"/>
                    <measurement group_id="O3" value="-1.19" spread="6.37"/>
                    <measurement group_id="O4" value="10.28" spread="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.84" spread="7.00"/>
                    <measurement group_id="O2" value="-1.27" spread="6.65"/>
                    <measurement group_id="O3" value="-3.13" spread="6.61"/>
                    <measurement group_id="O4" value="4.85" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.10" spread="7.76"/>
                    <measurement group_id="O2" value="-3.08" spread="8.23"/>
                    <measurement group_id="O3" value="-3.89" spread="6.77"/>
                    <measurement group_id="O4" value="4.04" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.08" spread="5.88"/>
                    <measurement group_id="O2" value="-0.64" spread="6.86"/>
                    <measurement group_id="O3" value="-1.65" spread="6.09"/>
                    <measurement group_id="O4" value="4.87" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="6.84"/>
                    <measurement group_id="O2" value="0.45" spread="6.85"/>
                    <measurement group_id="O3" value="0.81" spread="6.22"/>
                    <measurement group_id="O4" value="6.74" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-4.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.47</ci_lower_limit>
            <ci_upper_limit>-2.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-5.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.18</ci_lower_limit>
            <ci_upper_limit>-3.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-5.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.57</ci_lower_limit>
            <ci_upper_limit>-3.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-4.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.64</ci_lower_limit>
            <ci_upper_limit>-2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-4.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.87</ci_lower_limit>
            <ci_upper_limit>-2.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-2.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.90</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-1.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.86</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-1.66</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.77</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-1.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.17</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-2.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.58</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-2.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.87</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>0.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>2.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-4.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.57</ci_lower_limit>
            <ci_upper_limit>-2.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-2.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.59</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.02</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>1.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>3.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>1.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>3.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>2.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>4.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>4.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.48</ci_lower_limit>
            <ci_upper_limit>6.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>5.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.02</ci_lower_limit>
            <ci_upper_limit>7.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>2.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>4.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>1.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>1.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>3.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority (NI) margin for Lasmiditan doses versus (vs) Placebo is 10 milliseconds.</non_inferiority_desc>
            <param_type>LS Mean</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.44</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>7.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.72</ci_lower_limit>
            <ci_upper_limit>9.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>11.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.94</ci_lower_limit>
            <ci_upper_limit>13.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>10.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.16</ci_lower_limit>
            <ci_upper_limit>12.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>11.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.5</ci_lower_limit>
            <ci_upper_limit>13.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>10.81</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.9</ci_lower_limit>
            <ci_upper_limit>12.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>12.35</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.42</ci_lower_limit>
            <ci_upper_limit>14.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>12.65</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.76</ci_lower_limit>
            <ci_upper_limit>14.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>11.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.23</ci_lower_limit>
            <ci_upper_limit>13.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>8.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.02</ci_lower_limit>
            <ci_upper_limit>10.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>8.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.01</ci_lower_limit>
            <ci_upper_limit>10.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>6.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.23</ci_lower_limit>
            <ci_upper_limit>8.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>5.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.47</ci_lower_limit>
            <ci_upper_limit>8.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Cardiac Intervals: RR Interval of Lasmiditan and Moxifloxacin</title>
        <description>ECGs were used to calculate cardiac intervals. The RR interval is the time between two R waves.</description>
        <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and have evaluable RR interval data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin administered PO in 1 of 4 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Cardiac Intervals: RR Interval of Lasmiditan and Moxifloxacin</title>
          <description>ECGs were used to calculate cardiac intervals. The RR interval is the time between two R waves.</description>
          <population>All randomized participants who received at least 1 dose of study drug and have evaluable RR interval data.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 minutes postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.40" spread="76.26"/>
                    <measurement group_id="O2" value="98.52" spread="72.99"/>
                    <measurement group_id="O3" value="42.13" spread="56.00"/>
                    <measurement group_id="O4" value="18.66" spread="61.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.22" spread="77.73"/>
                    <measurement group_id="O2" value="153.15" spread="65.13"/>
                    <measurement group_id="O3" value="49.87" spread="62.40"/>
                    <measurement group_id="O4" value="9.63" spread="63.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.29" spread="80.63"/>
                    <measurement group_id="O2" value="130.79" spread="55.91"/>
                    <measurement group_id="O3" value="36.84" spread="66.52"/>
                    <measurement group_id="O4" value="13.44" spread="61.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.39" spread="60.84"/>
                    <measurement group_id="O2" value="128.10" spread="48.50"/>
                    <measurement group_id="O3" value="44.69" spread="53.70"/>
                    <measurement group_id="O4" value="26.01" spread="54.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.90" spread="73.85"/>
                    <measurement group_id="O2" value="132.86" spread="54.35"/>
                    <measurement group_id="O3" value="29.28" spread="51.39"/>
                    <measurement group_id="O4" value="26.90" spread="68.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.56" spread="63.82"/>
                    <measurement group_id="O2" value="119.52" spread="60.66"/>
                    <measurement group_id="O3" value="30.84" spread="57.28"/>
                    <measurement group_id="O4" value="24.87" spread="66.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.85" spread="56.54"/>
                    <measurement group_id="O2" value="101.86" spread="59.04"/>
                    <measurement group_id="O3" value="36.77" spread="50.34"/>
                    <measurement group_id="O4" value="19.01" spread="65.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.22" spread="57.19"/>
                    <measurement group_id="O2" value="83.00" spread="56.84"/>
                    <measurement group_id="O3" value="30.32" spread="51.11"/>
                    <measurement group_id="O4" value="13.64" spread="68.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.01" spread="69.03"/>
                    <measurement group_id="O2" value="-3.07" spread="63.34"/>
                    <measurement group_id="O3" value="-88.95" spread="60.15"/>
                    <measurement group_id="O4" value="-84.12" spread="63.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.63" spread="73.58"/>
                    <measurement group_id="O2" value="29.01" spread="66.89"/>
                    <measurement group_id="O3" value="-50.89" spread="75.72"/>
                    <measurement group_id="O4" value="-49.70" spread="52.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.70" spread="77.94"/>
                    <measurement group_id="O2" value="5.19" spread="73.16"/>
                    <measurement group_id="O3" value="-61.53" spread="76.51"/>
                    <measurement group_id="O4" value="-74.80" spread="70.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.37" spread="68.00"/>
                    <measurement group_id="O2" value="-5.64" spread="63.34"/>
                    <measurement group_id="O3" value="-11.66" spread="60.48"/>
                    <measurement group_id="O4" value="-13.02" spread="52.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>32.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.50</ci_lower_limit>
            <ci_upper_limit>54.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>100.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.81</ci_lower_limit>
            <ci_upper_limit>122.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>107.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.31</ci_lower_limit>
            <ci_upper_limit>130.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>74.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>56.32</ci_lower_limit>
            <ci_upper_limit>92.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>89.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.77</ci_lower_limit>
            <ci_upper_limit>109.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>74.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.41</ci_lower_limit>
            <ci_upper_limit>94.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>52.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.03</ci_lower_limit>
            <ci_upper_limit>69.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>42.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.86</ci_lower_limit>
            <ci_upper_limit>59.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>62.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.39</ci_lower_limit>
            <ci_upper_limit>82.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>56.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.49</ci_lower_limit>
            <ci_upper_limit>79.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>35.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.79</ci_lower_limit>
            <ci_upper_limit>59.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-4.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.66</ci_lower_limit>
            <ci_upper_limit>15.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>56.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.72</ci_lower_limit>
            <ci_upper_limit>76.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>103.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.88</ci_lower_limit>
            <ci_upper_limit>122.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>94.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75.15</ci_lower_limit>
            <ci_upper_limit>113.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>83.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.98</ci_lower_limit>
            <ci_upper_limit>99.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>103.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.28</ci_lower_limit>
            <ci_upper_limit>120.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>89.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71.24</ci_lower_limit>
            <ci_upper_limit>107.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>65.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.28</ci_lower_limit>
            <ci_upper_limit>82.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>52.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.10</ci_lower_limit>
            <ci_upper_limit>69.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>86.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>66.36</ci_lower_limit>
            <ci_upper_limit>105.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>80.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.32</ci_lower_limit>
            <ci_upper_limit>101.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>67.58</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.64</ci_lower_limit>
            <ci_upper_limit>90.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>7.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.01</ci_lower_limit>
            <ci_upper_limit>25.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-22.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.44</ci_lower_limit>
            <ci_upper_limit>-5.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-38.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.15</ci_lower_limit>
            <ci_upper_limit>-20.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-22.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.35</ci_lower_limit>
            <ci_upper_limit>-4.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-17.35</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.15</ci_lower_limit>
            <ci_upper_limit>-2.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.17</ci_lower_limit>
            <ci_upper_limit>16.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-4.77</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.81</ci_lower_limit>
            <ci_upper_limit>12.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-16.56</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.36</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-15.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.94</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>6.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.86</ci_lower_limit>
            <ci_upper_limit>23.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>2.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.25</ci_lower_limit>
            <ci_upper_limit>19.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-11.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.46</ci_lower_limit>
            <ci_upper_limit>9.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.32</ci_lower_limit>
            <ci_upper_limit>16.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Cardiac Intervals:QRS of Lasmiditan and Moxifloxacin</title>
        <description>ECGs were used to calculate cardiac intervals. The QRS interval is the time the segment of the ECG that corresponds to depolarization of the ventricles.</description>
        <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and have evaluable QRS data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin administered PO in 1 of 4 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Cardiac Intervals:QRS of Lasmiditan and Moxifloxacin</title>
          <description>ECGs were used to calculate cardiac intervals. The QRS interval is the time the segment of the ECG that corresponds to depolarization of the ventricles.</description>
          <population>All randomized participants who received at least 1 dose of study drug and have evaluable QRS data.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 minutes postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="1.12"/>
                    <measurement group_id="O2" value="-0.10" spread="1.23"/>
                    <measurement group_id="O3" value="0.09" spread="1.28"/>
                    <measurement group_id="O4" value="-0.00" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="1.21"/>
                    <measurement group_id="O2" value="0.45" spread="1.35"/>
                    <measurement group_id="O3" value="-0.02" spread="1.20"/>
                    <measurement group_id="O4" value="-0.12" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="1.13"/>
                    <measurement group_id="O2" value="0.19" spread="1.24"/>
                    <measurement group_id="O3" value="-0.37" spread="1.06"/>
                    <measurement group_id="O4" value="-0.12" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="1.12"/>
                    <measurement group_id="O2" value="0.10" spread="1.08"/>
                    <measurement group_id="O3" value="-0.30" spread="1.22"/>
                    <measurement group_id="O4" value="-0.29" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="1.41"/>
                    <measurement group_id="O2" value="0.30" spread="1.22"/>
                    <measurement group_id="O3" value="-0.21" spread="1.08"/>
                    <measurement group_id="O4" value="-0.20" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="1.21"/>
                    <measurement group_id="O2" value="0.08" spread="1.19"/>
                    <measurement group_id="O3" value="-0.26" spread="1.19"/>
                    <measurement group_id="O4" value="-0.35" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="1.00"/>
                    <measurement group_id="O2" value="0.15" spread="1.15"/>
                    <measurement group_id="O3" value="-0.17" spread="0.98"/>
                    <measurement group_id="O4" value="-0.57" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="1.03"/>
                    <measurement group_id="O2" value="0.29" spread="1.17"/>
                    <measurement group_id="O3" value="-0.20" spread="0.95"/>
                    <measurement group_id="O4" value="-0.58" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="1.43"/>
                    <measurement group_id="O2" value="0.64" spread="1.50"/>
                    <measurement group_id="O3" value="0.73" spread="1.34"/>
                    <measurement group_id="O4" value="0.13" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="1.36"/>
                    <measurement group_id="O2" value="-0.39" spread="1.43"/>
                    <measurement group_id="O3" value="-0.28" spread="1.38"/>
                    <measurement group_id="O4" value="-0.67" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="1.46"/>
                    <measurement group_id="O2" value="0.24" spread="1.67"/>
                    <measurement group_id="O3" value="0.63" spread="1.05"/>
                    <measurement group_id="O4" value="0.32" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="1.22"/>
                    <measurement group_id="O2" value="-0.07" spread="1.22"/>
                    <measurement group_id="O3" value="-0.10" spread="1.32"/>
                    <measurement group_id="O4" value="0.09" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.54</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.56</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Heart Rate (HR) of Lasmiditan and Moxifloxacin</title>
        <description>Heart rate was determined during ambulatory blood pressure monitoring (ABPM).</description>
        <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and have evaluable HR data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered PO in 1 of 4 treatment periods</description>
          </group>
          <group group_id="O2">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered PO in 1 of 4 treatment periods</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin administered PO in 1 of 4 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Heart Rate (HR) of Lasmiditan and Moxifloxacin</title>
          <description>Heart rate was determined during ambulatory blood pressure monitoring (ABPM).</description>
          <population>All randomized participants who received at least 1 dose of study drug and have evaluable HR data.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 minutes postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.90" spread="5.05"/>
                    <measurement group_id="O2" value="-5.51" spread="3.74"/>
                    <measurement group_id="O3" value="-2.41" spread="3.22"/>
                    <measurement group_id="O4" value="-1.02" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.82" spread="3.95"/>
                    <measurement group_id="O2" value="-8.40" spread="3.21"/>
                    <measurement group_id="O3" value="-2.77" spread="3.55"/>
                    <measurement group_id="O4" value="-0.42" spread="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.55" spread="4.16"/>
                    <measurement group_id="O2" value="-7.41" spread="3.14"/>
                    <measurement group_id="O3" value="-2.01" spread="3.53"/>
                    <measurement group_id="O4" value="-0.67" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.62" spread="3.22"/>
                    <measurement group_id="O2" value="-7.30" spread="2.93"/>
                    <measurement group_id="O3" value="-2.65" spread="3.17"/>
                    <measurement group_id="O4" value="-1.52" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.49" spread="4.07"/>
                    <measurement group_id="O2" value="-7.59" spread="3.27"/>
                    <measurement group_id="O3" value="-1.75" spread="2.97"/>
                    <measurement group_id="O4" value="-1.48" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.96" spread="3.32"/>
                    <measurement group_id="O2" value="-6.82" spread="3.53"/>
                    <measurement group_id="O3" value="-1.83" spread="3.35"/>
                    <measurement group_id="O4" value="-1.26" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.26" spread="3.02"/>
                    <measurement group_id="O2" value="-6.02" spread="3.50"/>
                    <measurement group_id="O3" value="-2.32" spread="3.06"/>
                    <measurement group_id="O4" value="-0.91" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.22" spread="3.06"/>
                    <measurement group_id="O2" value="-5.02" spread="3.42"/>
                    <measurement group_id="O3" value="-1.82" spread="3.19"/>
                    <measurement group_id="O4" value="-0.55" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="4.52"/>
                    <measurement group_id="O2" value="-0.10" spread="3.77"/>
                    <measurement group_id="O3" value="6.29" spread="5.18"/>
                    <measurement group_id="O4" value="5.84" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="4.73"/>
                    <measurement group_id="O2" value="-1.96" spread="3.93"/>
                    <measurement group_id="O3" value="3.42" spread="5.05"/>
                    <measurement group_id="O4" value="3.10" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="5.31"/>
                    <measurement group_id="O2" value="-0.50" spread="4.66"/>
                    <measurement group_id="O3" value="4.17" spread="5.46"/>
                    <measurement group_id="O4" value="4.95" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="4.45"/>
                    <measurement group_id="O2" value="0.42" spread="4.09"/>
                    <measurement group_id="O3" value="0.89" spread="3.96"/>
                    <measurement group_id="O4" value="0.81" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-1.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.90</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-5.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.29</ci_lower_limit>
            <ci_upper_limit>-3.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-5.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.81</ci_lower_limit>
            <ci_upper_limit>-4.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-4.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.00</ci_lower_limit>
            <ci_upper_limit>-3.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-4.78</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.91</ci_lower_limit>
            <ci_upper_limit>-3.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-4.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.20</ci_lower_limit>
            <ci_upper_limit>-3.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-2.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.87</ci_lower_limit>
            <ci_upper_limit>-2.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-2.42</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.42</ci_lower_limit>
            <ci_upper_limit>-1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-4.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.17</ci_lower_limit>
            <ci_upper_limit>-3.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-3.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.38</ci_lower_limit>
            <ci_upper_limit>-2.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-2.65</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.33</ci_lower_limit>
            <ci_upper_limit>-0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-3.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.16</ci_lower_limit>
            <ci_upper_limit>-2.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-5.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.65</ci_lower_limit>
            <ci_upper_limit>-4.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-5.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.42</ci_lower_limit>
            <ci_upper_limit>-4.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-4.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.55</ci_lower_limit>
            <ci_upper_limit>-3.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-5.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.77</ci_lower_limit>
            <ci_upper_limit>-4.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-4.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.03</ci_lower_limit>
            <ci_upper_limit>-3.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-3.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.68</ci_lower_limit>
            <ci_upper_limit>-2.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-3.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.21</ci_lower_limit>
            <ci_upper_limit>-2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-6.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.83</ci_lower_limit>
            <ci_upper_limit>-4.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-5.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.73</ci_lower_limit>
            <ci_upper_limit>-4.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-4.71</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.25</ci_lower_limit>
            <ci_upper_limit>-3.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.74</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>30 minutes postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>1.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>2.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>2.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>3.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>1.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>1.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>1.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>1.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.97</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>8 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.54</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>0.73</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>LS Mean</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incidents in Electrocardiogram (ECG) Abnormalities in QTcF Interval Greater Than 450 Milliseconds</title>
        <description>ECGs were assessed for morphology abnormalities or changes in QTcf interval greater than 450 milliseconds by a board-certified cardiologist</description>
        <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered PO in 1 of 4 treatment periods.</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin administered PO in 1 of 4 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incidents in Electrocardiogram (ECG) Abnormalities in QTcF Interval Greater Than 450 Milliseconds</title>
          <description>ECGs were assessed for morphology abnormalities or changes in QTcf interval greater than 450 milliseconds by a board-certified cardiologist</description>
          <population>All randomized participants who received at least 1 dose of study drug.</population>
          <units>Incidents</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan</title>
        <description>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan.</description>
        <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of lasmiditan.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered PO in 1 of 4 treatment periods</description>
          </group>
          <group group_id="O2">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered PO in 1 of 4 treatment periods</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan</title>
          <description>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan.</description>
          <population>All randomized participants who received at least 1 dose of lasmiditan.</population>
          <units>nanogram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.55" spread="41.452"/>
                    <measurement group_id="O2" value="526.15" spread="240.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan</title>
        <description>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan.</description>
        <time_frame>Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of lasmiditan.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>100 mg lasmiditan administered PO in 1 of 4 treatment periods</description>
          </group>
          <group group_id="O2">
            <title>400 mg Lasmiditan</title>
            <description>400 mg lasmiditan administered PO in 1 of 4 treatment periods</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan</title>
          <description>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan.</description>
          <population>All randomized participants who received at least 1 dose of lasmiditan.</population>
          <units>hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="684.66" spread="278.258"/>
                    <measurement group_id="O2" value="3189.08" spread="1152.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>75 days</time_frame>
      <desc>All randomized participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>100 mg Lasmiditan</title>
          <description>100 mg lasmiditan administered PO in 1 of 4 treatment periods.</description>
        </group>
        <group group_id="E2">
          <title>400 mg Lasmiditan</title>
          <description>400 mg lasmiditan administered PO in 1 of 4 treatment periods.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo administered PO in 1 of 4 treatment periods.</description>
        </group>
        <group group_id="E4">
          <title>Moxifloxacin</title>
          <description>Moxifloxacin administered PO in 1 of 4 treatment periods.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="55"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="55"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

